



Maria Teresa Peracchia is the Global Head of CMC Strategy & Execution in the Sanofi mRNA Center of Excellence, leading the CMC Project Leaders team and in charge of designing and aligning the End-to-End CMC strategy for the mRNA vaccine portfolio.

Maria-Teresa holds a Ph.D. in Pharmaceutics from the University of Parma, Italy. During her PhD, supervised by Professor Paolo Colombo, she was a Visiting Scientist (1992-1994) in Professor Robert Langer's lab at MIT, developing PEGylated polymeric nanoparticles. She was a post-doctoral fellow (1995-1998) with Prof. Patrick Couvreur at the University Paris-Saclay, focusing her work on the design of new PEGylated nanoparticles from polymer chemistry to in vivo biodistribution. During her PhD and postdoc, she has authored/ co-authored over 20 publications in the field of drug delivery and filed 8 patents.

Maria Teresa joined Sanofi in 1999. She held several positions of increasing responsibility in formulation development, drug delivery and CMC project management. From 2013 to 2019, she served as CMC Project Leader for Dupilumab (Dupixent®) developed in collaboration with Regeneron, where she led the CMC team through successful submission, registration and launch of Dupilumab for Atopic Dermatitis and Asthma indications. In her last role of Global Head of Drug Delivery of Biologics in the CMC Global Development organization, she established novel delivery technology capabilities at Sanofi through focused internal work and external partnerships.

Maria Teresa is deeply invested in the Controlled Release Society: she has been on the Board of Directors of the CRS since 2020, serving as Treasurer elect, Treasurer, Director at Large, and now secretary. She has been in the CRS Finance Committee from 2020 to 2025. As industry member and part of the IFC (Industry Foresight Council), that works with the CRS Board to better leverage the overall value that Industry can bring to the CRS community, Maria Teresa is exerting energy and passion in making sure the connection between CRS, Academia and the Industry keeps growing. Maria Teresa has a multicultural mindset and she has been working since the beginning of her career with US based teams, promoting US-EU bridges.

Maria Teresa has been elected to the American Institute for Medical and Biological Engineering (AIMBE) College of Fellows in 2020, and in 2025 her contribution to Drug Delivery has been recognized with the inaugural CRS Industry Achievement award.